Safety and antitumor activity of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with mesothelioma which is relapsed or refractory to standard therapies

M. Millward; S. Frentzas; H. K. Gan; A. Prawira; B. Tran; J. Coward; X. Jin; B. Li; M. Wang; K. Y. Kwek; Y. Xia; J. Desai

doi:10.1016/j.annonc.2020.08.1141

Safety and antitumor activity of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with mesothelioma which is relapsed or refractory to standard therapies

M. Millward, S. Frentzas, H. K. Gan, A. Prawira, B. Tran, J. Coward, X. Jin, B. Li, M. Wang, K. Y. Kwek, Y. Xia, J. Desai

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

8 Citations (Web of Science)

Original language	English
Article number	1021O
Pages (from-to)	S705-S706
Number of pages	2
Journal	Annals of Oncology
Volume	31
DOIs	https://doi.org/10.1016/j.annonc.2020.08.1141
Publication status	Published - Sept 2020
Externally published	Yes
Event	ESMO Virtual Congress 2020 - , Virtual Duration: 19 Sept 2020 → 21 Sept 2020

Access to Document

10.1016/j.annonc.2020.08.1141Licence: Other

Cite this

Millward, M., Frentzas, S., Gan, H. K., Prawira, A., Tran, B., Coward, J., Jin, X., Li, B., Wang, M., Kwek, K. Y., Xia, Y., & Desai, J. (2020). Safety and antitumor activity of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with mesothelioma which is relapsed or refractory to standard therapies. Annals of Oncology, 31, S705-S706. Article 1021O. https://doi.org/10.1016/j.annonc.2020.08.1141

@article{2b3ded606ae543c69c86baf2a36d86ee,

title = "Safety and antitumor activity of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with mesothelioma which is relapsed or refractory to standard therapies",

author = "M. Millward and S. Frentzas and Gan, {H. K.} and A. Prawira and B. Tran and J. Coward and X. Jin and B. Li and M. Wang and Kwek, {K. Y.} and Y. Xia and J. Desai",

year = "2020",

month = sep,

doi = "10.1016/j.annonc.2020.08.1141",

language = "English",

volume = "31",

pages = "S705--S706",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

note = "ESMO Virtual Congress 2020 ; Conference date: 19-09-2020 Through 21-09-2020",

}

Millward, M, Frentzas, S, Gan, HK, Prawira, A, Tran, B, Coward, J, Jin, X, Li, B, Wang, M, Kwek, KY, Xia, Y & Desai, J 2020, 'Safety and antitumor activity of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with mesothelioma which is relapsed or refractory to standard therapies', Annals of Oncology, vol. 31, 1021O, pp. S705-S706. https://doi.org/10.1016/j.annonc.2020.08.1141

Safety and antitumor activity of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with mesothelioma which is relapsed or refractory to standard therapies. / Millward, M.; Frentzas, S.; Gan, H. K. et al.
In: Annals of Oncology, Vol. 31, 1021O, 09.2020, p. S705-S706.

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

TY - JOUR

T1 - Safety and antitumor activity of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with mesothelioma which is relapsed or refractory to standard therapies

AU - Millward, M.

AU - Frentzas, S.

AU - Gan, H. K.

AU - Prawira, A.

AU - Tran, B.

AU - Coward, J.

AU - Jin, X.

AU - Li, B.

AU - Wang, M.

AU - Kwek, K. Y.

AU - Xia, Y.

AU - Desai, J.

PY - 2020/9

Y1 - 2020/9

U2 - 10.1016/j.annonc.2020.08.1141

DO - 10.1016/j.annonc.2020.08.1141

M3 - Abstract/Meeting Abstract

SN - 0923-7534

VL - 31

SP - S705-S706

JO - Annals of Oncology

JF - Annals of Oncology

M1 - 1021O

T2 - ESMO Virtual Congress 2020

Y2 - 19 September 2020 through 21 September 2020

ER -